The presence of tumour hypoxia is associated with an adverse prognosis in patients with head and neck squamous cell carcinomas (HNSCC) ([@bib21]). Similarly, low pretreatment haemoglobin (Hb) is associated with poor outcome for patients with HNSCC ([@bib16]; [@bib27]). Low Hb has been shown to correlate with poor tumour oxygenation ([@bib1]) and many clinicians take the view that anaemia and tumour hypoxia are causally linked. Therefore, packed red cell transfusions (PRCT) are frequently used to correct anaemia (Hb\<11.5 g dl^−1^) during radical chemo-radiation (CRT) for HNSCC and other squamous cell carcinomas ([@bib1]). However, in a retrospective analysis of 169 patients treated with CRT at our institution, PRCT was found to be a negative prognostic factor for relapse-free and overall survival ([@bib6]). Detrimental effects of PRCT have also been observed in patients having radical radiotherapy or surgery for non-HNSCC tumours ([@bib7]; [@bib34]; [@bib17]).

Attempting to minimise tumour hypoxia during CRT by giving PRCT assumes that low Hb accurately predicts tumour hypoxia and that increasing Hb will reliably reduce its presence. This is likely to be a significant oversimplification given the fact that tumour hypoxia is the result of several intrinsic and extrinsic factors, including many that are not directly related to Hb ([@bib15]). Therefore, we have studied the effect of PRCT on tumour oxygenation in a prospective cohort of patients who developed low Hb during radical CRT for HNSCC.

Intrinsic susceptibility-weighted (SWI) MRI characterised the oxygenation status within the tumour before and after PRCT. T~2~\* measured by SWI MRI is proportional to the total amount of deoxy-Hb in an imaging voxel and, by extension, the tissue partial pressure of oxygen. This parameter provides information on the oxygenation status of tumour tissue and previous research has shown that, in head and neck tumours, a change in T~2~\* can enable calculation of the corresponding change in pO~2~. ([@bib26]).

It is also possible that PCRT may deliver more than just Hb to the patient. For example, a unit of packed red cells may also contain cytokines and chemokines that may mediate effects on tumour and normal tissue vasculature that may influence tumour oxygenation. Therefore, we also measured circulating levels of biologically relevant cytokines/chemokines before and after PRCT.

Radiotherapy fractions delivered between pre- and post-PRCT MRI scans and cytokines present in PRCT may potentially have affected the tumour perfusion and vascular permeability. This, in turn, may have influenced tumour oxygenation and this was assessed using dynamic contrast-enhanced (DCE) immediately after SWI MRI.

Materials and methods
=====================

A prospective longitudinal cohort study was performed in patients with stages III--IV ([@bib12]) HNSCC undergoing radical CRT. All patients required PRCT during treatment owing to a fall in Hb to \<11.5 g dl^−1^. All patients had MRI-assessable disease of \>2 cm in diameter. Twelve healthy volunteers provided control serum samples. The study was approved by the institutional board and National Research Ethics Committee (no.12/LO/0631).

Treatment
---------

All but one patient received induction chemotherapy (IC) followed by radical CRT (cisplatin 100 mg m^−2^ days 1 and 29) according to institutional protocols (described in [Supplementary Section](#sup1){ref-type="supplementary-material"}). All patients were planned using simultaneous integrated boost intensity-modulated RT (SIB-IMRT) techniques ([@bib19]) delivering 65 Gy in 30 fractions over 6 weeks to the primary tumour and involved lymph nodes, and 54 Gy in 30 fractions to prophylactically treated nodal regions.

MRI data acquisition
--------------------

Patients were imaged on either a 3-T Philips Achieva or a 3-T Siemens Skyra MRI scanner using an eight-channel phased-array head coil. Anatomical coronal and axial T2W images were acquired first to assess the extent of the disease. SWI MRI was obtained using 2D GRE (Gradient Echo) (matrix 240, FOV: 240 × 240, 24 × 2.5 mm slices, FA=60, TR=1000 ms, TE: 4.6--39.1, delta 6.9 ms). DCE MRI was obtained using a 3D Spoiled GRE (TE/TR: 4.5/2.3 ms, matrix 160, FOV: 240 × 240, 24 × 2.5 mm slices, SENSE/GRAPPA parallel imaging: Philips (Amsterdam, Netherlands)/Siemens (Munich, Germany)). A series of 10 proton density-weighted volumes (flip angle, FA=3°) was initially acquired, followed by 100 T~1~W acquisitions (FA=16°) obtained sequentially with 3.5 s temporal resolution. Gadolinium-based contrast was injected intravenously at the start of the tenth dynamic scan as a bolus through a peripherally placed cannula using an automatic injector (0.2 ml per kg body mass, 2 ml s^−1^ injection rate, Dotarem, Guerbet, France) and followed by a saline flush (20 ml at 2 ml s^−1^).

DCE data were analysed using the software package MRIW (Institute of Cancer Research, London, UK) ([@bib11]) with the extended Kety model ([@bib33]) and a population-based arterial input function ([@bib24]). The volume transfer constant between blood plasma and extracellular extravascular space (*K*^trans^) was calculated for each voxel and displayed as a functional map. Signal changes on the multiple gradient echo images were used to calculate 3D T~2~\* relaxivity maps. SWI data processing was performed using the in-house MATLAB software (MathWorks, Natick, MA, USA).

Anatomical posttransfusion MRI images were manually co-registered to pretransfusion images using rigid body manipulation within the Pinnacle (Philips Radiation Oncology Systems, Fitchburg, MA, USA) Radiotherapy Treatment Planning System (RTPS). The resulting transformation matrices were then applied to the posttransfusion MRI parametric maps. Gross tumour volumes (GTV) for primary tumours and cervical lymph node metastases within the SWI and DCE MRI FOV were delineated on co-registered anatomical MR images by a head and neck oncologist (LW) and a radiologist (AR) using Pinnacle ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). 3D voxel-wise data from within the primary and nodal GTVs of the co-registered pretransfusion and posttransfusion *K*^trans^ and T~2~\* parametric maps were exported from Pinnacle for quantitative analysis using the in-house software written in R ([@bib28]) and MATLAB.

Serum markers of tumour hypoxia
-------------------------------

Peripheral blood samples were collected before (at the time of pretransfusion MRI) and 24 (at the time of posttransfusion MRI), 48 and 72 h after PRCT and on two separate days during the same week from healthy volunteers. Three to five milliliters of transfusate that remained in the bag after transfusion was collected for analysis. Blood samples were processed according to established standard operating procedures ([Supplementary Material](#sup1){ref-type="supplementary-material"}). A panel of 20 cytokines derived from a meta-gene signature established by ([@bib35]; [@bib8]) was measured in serum and transfusate by magnetic multiplex bead assay. The panel comprised: eotaxin, osteopontin (OPN), vascular endothelial growth factor (VEGF), interleukin (IL) IL-1*β*, IL-4, IL-8, IL-10, IL-12, IL-18, interferon (IFN-*α*), Gro-*α*, stromal cell-derived factor 1*α* (SDF1*α*), basic fibroblast growth factor (FGFb), tumour necrosis factor (TNF-*α*), transforming growth factor beta (TGF-*β*), platelet-derived growth factor (PDGF), granulocyte colony-stimulating factor (GCSF), hepatocyte growth factor (HGF), macrophage migration-inhibitory factor (MIF-1), and leptin. Multiplex magnetic bead assay kits were provided by Bio-Rad Laboratories (Bio-Rad, Hercules, CA, USA). Assays were performed in 96-well format according to the manufacturer\'s instructions. Cytokine concentrations were calculated based on a standard curve derived by performing eight serial dilutions of a protein standard in assay diluents. Serum samples were tested in duplicate, each sample was diluted 1 : 4 and 50 *μ*l was added to each well, and the mean values were calculated.

Statistics
----------

Voxelwise MRI parameter data were analysed using R. Histograms of T~2~\* and *K*^trans^ were plotted for each of the primary and lymph node tumours before and after infusion, and summary statistics were calculated. Bland--Altman limits of agreement (LOA) for T~2~\* (2.9 ms) and log~10~ *K*^trans^ (0.14 min^−1^) were determined based on separate reproducibility studies by ([@bib26]) for T~2~\* and unpublished work by Panek *et al* for *K*^trans^ (see [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). We also plotted changes of T~2~\* together with changes of volume transfer constant between blood plasma and extracellular extravascular space, to investigate whether MR relaxation time changes might be linked to vascular alterations induced by vasoactive cytokines present in PRC. Only changes of magnitude greater than the respective LOA were deemed to be statistically significant. Unpaired Wilcoxon tests were used to compare median serum protein concentrations between groups and paired Wilcoxon tests to compare differences in median serum cytokine concentrations.

Results
=======

Twenty patients were recruited to the study ([Table 1](#tbl1){ref-type="table"}). The primary tumour was located in the oropharynx in 15 patients (75%), of which 10 (66%) were human papillomavirus infection (HPV) positive. Seventeen patients (85%) had Hb within the gender-specific laboratory normal reference ranges (men: 13.0--17.0 g dl^−1^; women: 12.0--15.0 g dl^−1^) at pretreatment. At the time of PRCT, all patients had measureable disease. Seventeen (85%) patients had measurable primary tumours, and 13 (65%) patients had 19 measurable involved cervical LN metastases (range 1--3, [Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Anaemia and PRCT
----------------

Seventeen patients (85%) developed anaemia during treatment and three remaining patients were anaemic at presentation ([Table 2](#tbl2){ref-type="table"}). Patients were transfused at a median of 11 fractions of chemo-radiation (range 2--23 fractions). One patient (number 3; [Table 3](#tbl3){ref-type="table"}) developed symptomatic anaemia following two cycles of IC and, therefore, underwent PRCT immediately prior to starting chemo-radiation. Median Hb at the time of pretransfusion MRI scanning was 10.0 g dl^−1^ (range 9.4--11.4 g dl^−1^). A median of 2 units (range 1--3 units) of PRCs were transfused, resulting in an increment in Hb to a median of 12.3 g dl^−1^ (range 11.3--14.4 g dl^−1^) at the time of the posttransfusion MRI scan ([Table 2](#tbl2){ref-type="table"}).

Serum cytokine concentrations
-----------------------------

Median serum cytokine concentrations for volunteers and patients are shown in [Table 3](#tbl3){ref-type="table"}. There were no significant differences in the concentrations measured for volunteers on separate days. Measured serum concentrations for eight of the cytokines (IL-1*β*, IL-4, IL-8, IL-12, IFN-*α*, TNF-*α*, TGF-*β* and GCSF) were below the level of detection for both volunteers and patients, resulting in usable serum cytokine concentration data for only 12 of the 20 measured cytokines (Eotaxin, FGFb, GRO-*α*, HGF, IL-10, IL-18, Leptin, MIF, OPN, PDGF, SDF1*α*, VEGF). There were no statistically significant changes in median serum concentrations for any of the cytokines when measured at the time of pretransfusion and posttransfusion MRI scans ([Table 3](#tbl3){ref-type="table"}). Each of the 12 serum cytokines measurable in both patients and volunteers were also measurable in PRC transfusate ([Table 3](#tbl3){ref-type="table"}). The level of MIF in the transfusate was significantly higher than in volunteer serum (*P*\<0.0001). The concentrations of OPN (*P*\<0.001) and MIF (*P*=0.02) in the patients\' sera were significantly higher than in volunteers both before and after the transfusion.

MRI parameters of tumour hypoxia
--------------------------------

Pre- and post-PRCT T~2~\* and *K*^trans^ were evaluable for primary tumours in 16 patients and for LN metastases in 13 patients. These are summarised in [Table 2](#tbl2){ref-type="table"} (statistically significant net changes) and [Supplementary Table S1](#sup1){ref-type="supplementary-material"} (median voxel-wise changes). Scatterplots showing change in median T~2~\* *versus* change in log~10~ median *K*^trans^ for primary tumours and lymph nodes are detailed in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, respectively. Only changes of magnitude greater than the respective LOA are statistically significant. As seen in [Figure 1](#fig1){ref-type="fig"}, improved tumour oxygenation in primary tumours was observed in four patients (nos. 1, 12, 15 and 19). [Figure 2](#fig2){ref-type="fig"} shows that similar changes in tumour oxygenation were not observed in the lymph nodes in these four patients. Similarly, no change in primary tumour oxygenation was observed in two patients (nos. 4 and 6) for whom involved lymph nodes showed improved oxygenation, demonstrating a differential response in primary tumours and lymph nodes to PCRT. No change in primary tumour oxygenation was observed in 11 patients (no. 2--6, 8, 10, 13, 14, 18 and 20). Reduced primary tumour oxygenation and perfusion was observed in one patient (no. 17).

No statistically significant associations were found between median T~2~\* or median *K*^trans^ and the median serum concentrations of any of the measured cytokines for either primary tumours or LNs. Therefore, neither the radiation delivered between pre- and post-PRCT scans nor the cytokines present in the transfusate altered perfusion or vascular permeability in the tumour to a degree sufficient to affect tissue oxygenation.

Treatment outcomes
------------------

Treatment outcomes at 3 months post-CRT are summarised in [Table 2](#tbl2){ref-type="table"}. Complete clinical and radiological responses (CR) to CRT at this time were achieved for 11 out of 20 (55%) patients, but the remaining 9 out of 20 (45%) patients had evidence of persistent or progressive disease (PD). Three of the four patients (nos. 12, 15 and 19) who demonstrated improved primary tumour oxygenation ([Figure 1](#fig1){ref-type="fig"}) had PD ([Table 2](#tbl2){ref-type="table"}). Therefore, the observed magnitude of improved tumour oxygenation following PRCT did not translate into improved treatment outcomes in these patients.

Correlations between MRI parameters and blood Hb
------------------------------------------------

The relationships between change in blood Hb and change in median T~2~\* and median *K*^trans^ for primary tumours and cervical LN metastases are summarised in [Figures 3A and B](#fig3){ref-type="fig"}. There was no significant correlation between change in Hb and change in primary tumour median T~2~\* following PRCT (Kendall\'s tau −0.286, *P*=0.13).

Discussion
==========

In this study, we have used SWI MRI to characterise the change in oxygenation status within tumours before and after PRCT. As T~2~\* is proportional to the total amount of deoxy-Hb in an imaging voxel ([@bib23]) and, by extension, the tissue partial pressure of oxygen, this parameter provides information on the oxygenation status of tumour tissue ([@bib26]). An absolute measurement of tumour oxygen partial pressure using SWI MRI poses a serious challenge as it requires knowledge on additional confounding factors, such as blood volume and tissue hematocrit ([@bib36]). In addition, local magnetic field inhomogeneity induced by air--tissue boundaries or the presence of metallic implants can also affect T~2~\* susceptibility measurements. In this study, changes in T~2~\* rather than absolute values were used. By measuring T~2~\* before and after PRCT, the effect of factors other than change in Hb should be controlled, leaving change in tissue deoxy-Hb as the main factor driving change in T~2~\*. The variation of T~2~\* due to different patient positioning and MR system optimisation (i.e., iterative local field shimming) were taken into account adopting 3T repeatability thresholds calculated in a cohort of HNSCC patients ([@bib26]). It would be interesting to extend such analysis to hypoxia-specific PET markers ([@bib18]), which could help to identify severely hypoxic regions of HNSCC tumours. Similarly, MR imaging could be used to identify avascular parts of tumour, such as necrotic lymph nodes, with impaired delivery of a PET tracer.

This study demonstrates that tumour oxygenation remained stable (11 out of 16) or was significantly reduced (1 out of 16) following PRCT in 12 out 16 (75%) evaluable patients ([Figure 1](#fig1){ref-type="fig"}). In addition, for three of the four patients with improved tumour oxygenation following PRCT, this did not translate into improved outcome (nos. 12, 15, and 19, [Table 3](#tbl3){ref-type="table"}). For the four primary tumours with a significant increase in median T~2~\* after PRC transfusion, the median increase was 4.3 ms (range 3.3--8.4) corresponding to an approximate increase in median tumour tissue oxygen tension of the order of 4 mm Hg ([@bib26]). The overall magnitudes of these observed increases in median T~2~\* are relatively small and correspond to changes in tissue pO~2~ that are unlikely to be of radiobiological significance and would not therefore be expected to influence treatment outcome.

In addition, it is possible that anaemia and hypoxia act independently and that tumours with a more aggressive adverse phenotype cause anaemia via activation of catabolic pathways, increased secretion of inflammatory cytokines, extracorpuscular haemolysis and reduction in the level of haematopoetic precursors ([@bib13]). The CR rate of 55% in patients who developed anaemia was inferior to CR rates of ∼75% that we have previously reported in an unselected group of patients ([@bib5]; [@bib19]). This supports the assertion that patients who develop anaemia may have more aggressive tumours with poor prognosis. The transitory reversal of anaemia using PRCT is unlikely to reverse the biology underlying the anaemia and improve treatment outcomes.

Previous studies have demonstrated that pro-inflammatory cytokines are present in leucocyte-depleted and non-depleted blood and that their concentration increases with storage time ([@bib2]). We hypothesised that PRC transfusate might contain physiologically significant concentrations of vasoactive and pro-inflammatory cytokines that could influence tumour hypoxia, vasculature and growth, independent of changes in blood Hb. Our data demonstrate that vasoactive and pro-inflammatory cytokines are present in PRC, in agreement with previous studies. MIF was the only cytokine that was present in PRC in significantly greater concentration than in serum from healthy volunteers ([Table 3](#tbl3){ref-type="table"}). However, there was no statistically significant change in the concentration of any of the measured serum cytokines following PRCT, including MIF.

We specifically investigated the possibilities that cytokines present in PRCT, or radiotherapy fractions delivered between pre- and post-PRCT MRI scans, might affect tumour perfusion and/or vascular permeability, by calculating tumour *K*^trans^ from DCE MRI. Only small changes in median *K*^trans^ across PRCT, for both primary tumours and LNs, were observed ([Table 2](#tbl2){ref-type="table"}; [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Cytokines present in the PRCT, or radiotherapy fractions delivered between pre- and post-PRCT MRI scans, are therefore unlikely to have resulted in changes in tumour vasculature and/or vessel permeability. Therefore, we can conclude that it is unlikely that PRCT results in administration of biologically significant quantities of cytokines that might enhance tumour growth or alter tumour vasculature and vessel permeability. The median *K*^trans^ values were in agreement with a range of values reported for stage IV HNSCC in the literature ([@bib10]; [@bib29]; [@bib3]).

Our study included small patient numbers. However, it included a spectrum of HNSCC tumour profiles encountered in clinical practice for radical non-surgical treatment, such as oropharyngeal (HPV positive and negative), laryngeal and hypopharyngeal cancers. In addition, we have attempted to minimise bias by using LOA set by previous studies on MRI reproducibility ([@bib26]) to determine the clinical relevance of observed changes in MRI parameters and by using adequate controls when analysing the cytokine data. In this study, we have only studied the effect of PRCT on changes in tumour oxygenation and have not modelled the other effects of PRCT on the tumour and the patient.

Many institutions follow a policy of using PRCT to maintain Hb levels \>12 g dl^−1^ during radical treatment for HNSCC and other tumour types under the assumption that this mitigates hypoxia-induced radio-resistance. This is based on older studies that have correlated low Hb with reduced tumour oxygenation and adverse outcomes ([@bib31]; [@bib30]; [@bib1]). Our data obtained using modern imaging and molecular techniques do not support the hypothesis that PRCT improves oxygenation and tumour outcomes. Given the existing clinical data demonstrating lack of benefit for PRCT in HNSCC patients ([@bib14]; [@bib13]), our data add significant weight to concerns that current clinical practice of routine PRCT during radical treatment for HNSCC to enhance tumour oxygenation may be futile. Importantly, however, our study has demonstrated that PRCT does not contain biologically significant quantities of cytokines that could promote tumour growth. PRCT, therefore, may be administered for other clinical indications and should be carried out as per relevant expert guidelines, such as those of NICE and American Association of Blood Banks guidelines on PRCT for anaemia ([@bib20]; [@bib9]). These guidelines do not recommend routine PRCT for Hb⩾10 g dl^−1^. The only definite indication for PRCT is Hb\<7 g dl^−1^ or Hb\<8 g dl^−1^ in patients with reduced tolerance for anaemia (aged \>65 years and with preexisting cardiovascular and/or respiratory disorders). In addition, change in clinical practice would help mitigate the impact of projected future shortages of blood products (as predicted by NHS Blood and Transplant) as well as preventing unnecessary exposure of patients to the risks associated with PRCT.

Hypoxia-induced treatment resistance is still a problem in HNSCC management and alternative strategies such as hypoxic sensitisers such as nimorazole or vascular-targeting agents should be explored ([@bib25]; [@bib22]) using a personalised targeted strategy based on molecular hypoxic signatures ([@bib4]; [@bib32]).
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###### 

Click here for additional data file.

![**Scatterplot showing change in median T~2~\* *versus* change in median *K*^trans^ (log~10~transformed) for primary tumours.** Dashed lines show Bland--Altman limits of agreement.](bjc2016386f1){#fig1}

![**Scatterplot showing change in median T~2~\* *versus* change in median *K*^trans^ (log~10~transformed) for cervical lymph node tumours.** Dashed lines show Bland--Altman limits of agreement.](bjc2016386f2){#fig2}

![**Barplots summarising the relationship between changes in median T~2~\*, median *K*^trans^, and blood cHb before and after PRC transfusion for primary tumours (**A**) and LNs (**B**).**  ](bjc2016386f3){#fig3}

###### Summary of patient and tumour characteristics

  ------------------------------- -------------
  Number of patients                   20
  Age (years), median (range)      62 (53--70)
  Sex (%)                                
   Female                            6 (30)
   Male                              14 (70)
  Primary site (%)                       
   Oropharynx                        15 (75)
   Hypopharynx/larynx                4 (20)
   Sinonasal                          1 (5)
  HPV status for oropharynx (%)          
   Positive                          10 (66)
   Negative                          5 (34)
  T-stage (%)                            
   1                                  1 (5)
   2                                 7 (35)
   3                                 7 (35)
   4                                 5 (25)
  N-Stage (%)                            
   0                                 3 (15)
   1                                 2 (10)
   2                                 15 (75)
  Induction chemotherapy (%)             
   Cisplatin/5-FU                    8 (40)
   Carboplatin/5-FU                  5 (25)
   TPF                               6 (30)
   None                               1 (5)
  Concomitant chemotherapy (%)           
   Cisplatin                         9 (45)
   Carboplatin                       11 (55)
  Hb at first presentation (%)           
   \<11.5 g dl^−1^                   3 (15)
   \>11.5 g dl^−1^                   17 (85)
  ------------------------------- -------------

Abbreviations: Hb=haemoglobin; HPV=human papillomavirus; TPF=docetaxel, cisplatin, 5-fluorouracil; 5-FU=5-fluorouracil.

###### Summary of outcome data 3 months after RT with median *K* ^trans^ and T~2~\* changes after blood transfusion

                                           **Primary**   **Lymph nodes**                      
  ---- -------------- ----- ------ ------ ------------- ----------------- --------- --------- ----
  1       T3N1 OPC     −ve  9.4    10.6         ↑              No            No        NA      CR
  2       T2N1 OPC     +ve  10.5   13.7        No              No           No, ↓     ↑, No    CR
  3      T2N2b OPC     +ve  9.7    13.2        No              No             ↓        No      CR
  4      T2N2a OPC     +ve  9.9    14.1        No               ↑             ↑        No      CR
  5     T4N0 HypoPC    Unk  11.3   12.6        No              No            ---       ---     PD
  6     T4N2c Larynx   Unk  9.8    11.3        No              No          No,↑, ↑   No,↑, ↑   PD
  7     T3N2c Larynx   Unk  10.2   11.7        No              NA             ↓        NA      CR
  8       T3N0 OPC     −ve  9.5    11.5        No              No            ---       ---     CR
  9      T3N2b OPC     +ve  10.3   12.6        ---             ---            ↓        No      CR
  10     T4N2c OPC     +ve  10.2   11.3        No              No            ---       ---     PD
  11     T1N2c OPC     −ve  9.5    14.4        ---             ---          No, ↓     No,↑     PD
  12     T3N2b OPC     −ve  10.6   11.7         ↑              No             ↓         ↑      PD
  13    T4N0 Ethmoid   Unk  9.7    12.6        No              No            ---       ---     PD
  14     T2N2c OPC     +ve  9.5    12.1        No               ↑             ↓        No      CR
  15     T3N2c OPC     +ve  11.4   12.3         ↑               ↑            ---       ---     PD
  16     T2N2a OPC     +ve  10.4   12.3        NA              NA             ↓         ↓      CR
  17    T2N2b Larynx   Unk  11.4   12.5         ↓               ↓            NA        NA      PD
  18     T4N2c OPC     +ve  9.7    11.4        No              No            No         ↓      CR
  19     T2N2b OPC     −ve  10.1   11.8         ↑               ↑          No, No     No,↓     PD
  20     T3N2b OPC     +ve  9.7    11.5        No              No            No         ↑      CR

Abbreviations: CR=complete remission; Hb=haemoglobin; HPV=human papillomavirus; NA=insufficient or poor quality data for analysis; PD=persistent or progressive disease; RT=radiation therapy.

###### Summary of median serum concentration (pg ml^−1^) of the panel of hypoxia-associated cytokines for healthy volunteers and patients and the median concentration (pg ml^−1^) of the same panel of cytokines in the PRC transfusate

                                                                     **Patients**                                           
  --------- -------- -------- ---------- -------- ------- ---------- -------------- -------- ---------- ---------- -------- ----------
  Eotaxin   27.0     4.4      78.5       10.8     3.3     83.4       36.6           4.7      9965.4     24.9       15.7     10 114.6
  OPN       5178.2   2466.9   11 483.2   2095.6   486.5   24 578.2   13 258.0       1853.7   18 647.8   12 632.9   2024.0   21 178.8
  HGF       47.9     24.1     124.4      14.0     4.28    4426.8     65.6           18.7     9714.8     60.3       14.4     7418.6
  MIF       26.9     11.8     77.5       799.5    20.6    5461.3     38.0           10.9     761.9      47.5       15.7     612.6
  GRO*α*    21.3     12.6     54.0       14.6     1.54    24.9       18.6           0.0      102.8      14.9       0.0      55.1
  PDGF      958.9    280.7    1469.2     5.8      0.8     470.6      472.9          12.5     1161.4     387.0      21.2     1467.6
  VEGF      11.3     3.5      47.6       7.6      1.3     33.9       23.6           1.9      264.3      28.2       7.4      274.0
  SDF1*α*   182.1    98.8     241.1      13.7     4.62    161.5      126.7          41.6     405.4      112.0      69.0     495.2
  FGFb      5.4      0.0      11.3       5.6      0.6     34.0       2.7            0.8      9.3        4.1        0.5      11.4
  Leptin    646.8    71.8     6886.2     218.5    17.9    3237.4     1965.5         55.7     14 519.1   856.8      84.0     7469.6
  IL-18     11.2     6.7      33.3       7.1      2.0     23.3       13.9           5.6      603.8      14.0       5.7      660.5
  IL-10     0.0      0.0      19.8       0.8      0.0     4.2        0.8            0.0      2177.35    0.3        0.0      1436.6

Abbreviations: FGFb=basic fibroblast growth factor; GRO*α*=growth regulated alpha protein; HGF=hepatocyte growth factor; IL=interleukin; MIF=migration-inhibitory factor; MRI=magnetic resonance imaging; OPN=osteopontin; PDGF=platelet-derived growth factor; PRC=packed red cell; SDF1*α*=stromal cell-derived factor 1*α*; VEGF=vascular endothelial growth factor.
